In the world of small-molecule generics, firms that move from developing off-patent medicines towards focusing on innovative drugs are sometimes described as “poacher turned gamekeeper,” reflecting the change in mindset that comes when moving from a position of targeting brands to defending them.
In the biologics arena, however, Amgen has done the opposite, with the originator branching out into the world of...